Cellectar Biosciences, Inc.
CLRBHealthcare|Biotechnology|US
$1.25
+0.10 (+8.70%)
DCF Value
$4.39
Tangible Book / Share
$2.44
Cash / Share
$2.78
Clinical Trials (18)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT02952508 Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom | Waldenstrom Macroglobulinemia, Multiple Myeloma | P2 | Active | 120 | Open-label | Iopofosine I 131 single dose, Iopofosine I 131 multiple dose, Iopofosine I 131 fractionated dose |
| NCT05610891 Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG | High-Grade Glioma | P1 | Active | 50 | Open-label | CLR 131 |
| NCT03478462 Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas | Pediatric Solid Tumor, Pediatric Lymphoma | P1 | Active | 30 | Open-label | CLR 131 |
| NCT07311993 Phase 1 Study of CLR 125 in Triple Negative Breast Cancer | Breast Cancer | P1 | Recruiting | 60 | RCT, Open-label | Iopofosine I 131, CLR 125 |
| NCT00347412 Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer | Non Small Cell Lung Cancer | P3 | Completed | 903 | RCT, Open-label | Paclitaxel, NOV-002, Carboplatin |
| NCT07766421 Evaluation of Iopofosine I 131 vs. R-CD in WM Patients | Waldenstrom Macroglobulinaemia, Waldenstrom Macroglobulinemia | P3 | Not Yet Recruiting | 219 | RCT, Open-label | Iopofosine I 131, Rituximab (active comparator), Cyclophosphamate, Dexamethasone |
| NCT01898273 Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma | Glioblastoma | P2 | Terminated | 7 | Open-label | I-124-CLR1404 |
| NCT01778088 Open-Label Study of I-131-CLR1404 in Subjects With Recurrent Glioma | Glioma | P2 | Withdrawn | — | Open-label | I-131-CLR1404 Injection |
| NCT00960726 NOV-002 in Myelodysplastic Syndrome (MDS) | Leukemia, Myelodysplastic Syndrome | P2 | Withdrawn | — | Open-label | NOV-002 |
| NCT00345540 Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-resistant Ovarian Cancer | Ovarian Cancer | P2 | Completed | 15 | Open-label | NOV-002, Carboplatin |
| NCT01058512 A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy | Hepatitis C | P2 | Completed | 22 | Open-label | NOV-205 |
| NCT02278315 Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma | Multiple Myeloma | P1 | Completed | 31 | Open-label | I-131-CLR1404, dexamethasone, I-131-CLR1404 |
| NCT04105543 CLR 131 Combined With Radiation for Head and Neck Cancer | Head and Neck Cancer | P1 | Completed | 12 | Open-label | CLR 131 |
| NCT01495663 Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned | Cancer | P1 | Completed | 12 | Open-label | I-131-CLR1404 |
| NCT00582283 NM404 as an Imaging Agent in Patients With NSCLC | Non Small Cell Lung Cancer | P1 | Completed | 21 | Open-label | I124-NM404 |
| NCT00372983 Safety and PK Study of NOV-205 to Treat Chronic HCV Who Fail Standard Therapy | Hepatitis C | P1 | Completed | 30 | RCT, Double-blind | NOV-205 |
| NCT00925275 Dosimetry Study of I-131-CLR1404 in Patients With Relapsed or Refractory Advanced Solid Tumors | Solid Tumors | P1 | Completed | 9 | Open-label | I-131-CLR1404 |
| NCT01662284 Study of 124I-NM404 in Advanced Solid Malignancies | Triple Negative Breast, Prostate, Colorectal, Gastric, Ovarian, Pancreatic, Esophageal, Soft Tissue Sarcoma, and Head & Neck Cancer | Terminated | 12 | — | 124I-NM404 |